Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Marea Therapeutics, Inc.

News headline image
Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Forms Clinical Scientific Advisory Board
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly
From Marea Therapeutics, Inc.
Via Business Wire
News headline image
Marea Therapeutics Expands Management Team and Board of Directors
From Marea Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.